Indivior PLC (LON:INDV) has revealed that its wholly-owned US subsidiary has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film.
In a statement, the FTSE 250-listed dugs group said the Californian agency, which is charged with overseeing insurance regulations, requested documents from its US unit relating to the preparation of the drug, manufacturing records, and the potential to develop dependency on the treatment.
READ: Indivior settles patent infringement litigation related to Suboxone drug
The firm, which was spun out from Reckitt Benckiser PLC (LON:RB.) in 2014 said: “Indivior intends to comply with the CDI’s subpoena and will cooperate in any related government inquiry.”
Earlier this month, Indivior reached an agreement with a group of drug companies to settle litigation over patent infringement of its Suboxone opioid addiction treatment.
The company said it settled with Par Pharmaceutical Inc., Par Pharmaceutical Companies Inc., Endo International PLC (referred to collectively as Par) and IntelGenx Technologies Corp.